Our client is looking for a Database Developer to design, implement, and maintain in-house database systems and support related data management products. This role involves full-cycle database ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Confirming it has reached 3 million weekly developers, OpenAI is massively updating its Codex developer environment via its Mac and Windows desktop apps today to bring it closer to the “Super App” the ...

For decades, academic institutions have struggled with how to prevent researchers who have committed misconduct from securing jobs at other universities while hiding the bad behaviour. A proposal ...

Microsoft unveiled .NET Aspire at the Build 2024 developer conference, describing it as an opinionated, cloud-ready stack for building observable, production ready, distributed, cloud-native ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Recently we were introduced to OpenClaw, an AI that allows users to create their own agents to control apps like email, Spotify and home controls. Now, Sam Altman has announced that OpenAI has ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...